Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine

International Journal of Cancer

Volumn 72, Issue 6, 1997, Pages 972-976

  Reynolds, Sandra R ^a   Oratz, Ruth ^b   Shapiro, Richard L ^b   Hao, Phyllis ^b   Yun, Zhang ^c   Fotino, Marilena ^c   Vukmanović, Stanislav ^b   Bystryn, Jean Claude ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c ROGOSIN INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MELANOMA VACCINE; PEPTIDE; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOCOMPETENCE; MELANOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; EPITOPES; HLA-A2 ANTIGEN; HUMANS; MELANOMA; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0030765987     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970917)72:6<972::AID-IJC9>3.0.CO;2-M     Document Type: Article

References (17)

1. BLUM-TIROUVANZIAM, U., SERVIS, C., HABLUETZEL, A., VALMORI, D., MEN, Y., ESPOSITO, F., DEL NERO, L., HOLMES, N., FASEL, N. and CORRADIN, G., Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum. J. Immunol. 154, 3922-3931 (1995).
2. BOON, T. and VAN DER BRUGGEN, P., Human tumor antigens recognized by T lymphocytes. J. exp. Med., 183, 725-729 (1996).
3. BYSTRYN, J.-C., HENN, M., LI, J., and SHROBA, S., Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res., 52, 5948-5953 (1992).
4. BYSTRYN, J.-C., JACOBSEN, S., HARRIS, M.N., ROSES, D.F., SPEYER, J.L., and LEVIN, M., Preparation and characterization of a polyvalent human melanoma antigen vaccine. J. biol. Resp. Mod., 5, 221-224 (1986).
5. BYSTRYN, J.-C., SHAPIRO, R.L. and ORATZ, R., Partially purified tumor antigens. In: V.T. DeVita, S. Hellman, and S.A. Rosenberg (eds), Biologic Therapy of Cancer (2nd ed.), pp. 668-679, J.B. Lippincott, Philadelphia, PA (1995).
6. COULIE, P.G., BRICHARD, V., VAN PEL, A., WÖLFEL, T., SCHNEIDER, J., TRAVERSARI, C., MATTEI, S., DE PLAEN, E., LURQUIN, C., SZIKORA, J.-P., RENAULD, J.-C., and BOON, T., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. exp. Med., 180, 35-42 (1994).
7. COX, A.L., SKIPPER, J., CHEN, Y., HENDERSON, R.A., DARROW, T.L., SHABANOWITZ, J., ENGELHARD, V.H., HUNT, D.F., CRAIG, L. and SLINGLUFF, C.L., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science, 264, 716-719 (1994).
8. GAUGLER, B., VAN DEN EYNDE, B., VAN DER BRUGGEN, P., ROMERO, P., GAFORIO, J.J., DE PLAEN, E., LETHÉ, B., BRASSEUR, F. and BOON, T., Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. exp. Med., 179, 921-130 (1994).
9. GERSHMAN, N., JOHNSTON, D. and BYSTRYN, J.-C., Potentiation of B16 melanoma vaccine immunogenicity by IL-2 liposomes. Vaccine Res., 3, 82-93 (1994).
10. KASAIAN, M.T., IKEMATSU, H. and CASALI, P., Identification and analysis of a novel human surface CD5-B lymphocyte subset producing natural antibodies. J. Immunol., 148, 2690-2702 (1992).
11. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K., ROBBINS, P.F., RIVOLTINI, L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Identification of the immunodominant peptides of the Melan A/MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. exp. Med., 180, 347-352 (1994).
12. + T cells using an ELISPOT assay. J. immunol. Meth., 181, 45-54 (1995).
13. OLERUP, O. and ZETTERQUIST, H., HLA DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens, 39, 225-235 (1992).
14. RUSSO, V., TRAVERSARI, C., VERRECCHIA, A., MOTTOLESE, M., NATALI, P.G. and BORDIGNON, C., Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int. J. Cancer, 64, 216-221 (1995).
15. TRAVERSARI, C., VAN DER BRUGGEN, P., LUESCHER, I.F., LURQUIN, C., CHOMEZ, P., VAN PEL, A., DE PLAEN, E., AMAR-COSTESEC, A. and BOON, T., A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. exp. Med., 176, 1453-1457 (1992).
16. VAN DER BRUGGEN, P., BASTIN, J., GAJEWSKI, T., COULIE, P.G., BOËL, P., DE SMET, C., TRAVERSARI, C., TOWNSEND, A. and BOON, T., A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Europ. J. Immunol., 24, 3038-3043 (1994).
17. WÖLFEL, T., VAN PEL, A., BRICHARD, V., SCHNEIDER, J., SELIGER, B., MEYER ZUM BÜSCHENFELDE, K.-H., and BOON, T., Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Europ. J. Immunol., 24, 759-764 (1994).